GC Corp.
Financials
Valuation Metrics
GC Corp.'s Market Cap is ₩4536B. At end of 2025 it was ₩7710B. Ranked #465 of 2,436 in KR market (top 19%), #295 of 787 on KOSPI (top 37%), #53 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 453.62B KRW | KR#465/2,436 Sec#53/234 |
| Revenue | 2.49T KRW | KR#216/2,436 Sec#3/234 |
| Net Income | -41.82B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 4.07T KRW | KR#194/2,436 Sec#4/234 |
| Net Assets | 1.76T KRW | KR#197/2,436 Sec#7/234 |
| Employees | 155 | KR#1,290/2,436 Sec#105/234 |
| Value | ||
| P/B | 0.26x | KR#236/2,436 Sec#7/234 |
| P/S | 0.18x | KR#317/2,436 Sec#3/234 |
| EV/EBITDA | 39.50x | KR#1,283/2,436 Sec#87/234 |
| FCF Yield | -19.08% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -2.37% | KR#1,637/2,436 Sec#115/234 |
| ROA | -1.03% | KR#1,599/2,436 Sec#112/234 |
| Op. Margin | 1.77% | KR#1,386/2,436 Sec#100/234 |
| Revenue Growth | 8.13% | KR#1,013/2,436 Sec#93/234 |
| Earnings Growth | -150.68% | KR#1,450/2,436 Sec#95/234 |
| Financial Health | ||
| Debt Ratio | 130.71% | KR#868/2,436 Sec#100/234 |
| Total Debt | 1.37T KRW | KR#158/2,436 Sec#2/234 |
| FCF | -86.57B KRW | KR#2,133/2,436 Sec#212/234 |
| Cash | 81.50B KRW | KR#531/2,436 Sec#28/234 |
| Current Ratio | 0.94x | KR#1,882/2,436 Sec#188/234 |
| Net Debt/EBITDA | 29.20x | KR#1,474/2,436 Sec#103/234 |
| Dividend | ||
| Div. Yield | 3.20% | KR#623/2,436 Sec#27/234 |
| Div. Growth | -40.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -35.70% | KR#1,730/2,436 Sec#153/234 |
| 1M Return | -5.11% | KR#1,406/2,436 Sec#144/234 |
| From 52W High | -45.31% | KR#995/2,436 Sec#79/234 |
| 1Y MDD | -47.35% | KR#808/2,436 Sec#69/234 |
| Trading | ||
| Volume | 76,853 shares | KR#1,095/2,436 Sec#106/234 |
| Foreign Own. | 8.41% | KR#543/2,436 Sec#48/234 |
| Per Share | ||
| EPS | -1,812 KRW | KR—/2,436 Sec—/234 |
| BPS | 19,023 KRW | KR#538/2,436 Sec#37/234 |
Company Info
Established in 1967 and headquartered in Yongin, Gyeonggi, Green Cross Holdings transitioned into a holding company in 2001. It oversees a total of 56 domestic and international corporate affiliates, led by Green Cross, primarily in biotechnology and healthcare. The company performs holding company roles such as management strategy and investment asset portfolio management, while actual business operations are handled by its subsidiaries. In 2025, it expanded its business scope by acquiring ABO Holdings to enter the US blood center business and consolidating 15 new companies including Bibros.